Read by QxMD icon Read

European Journal of Cancer

Ana M Molina, Thomas E Hutson, Dmitry Nosov, Piotr Tomczak, Oleg Lipatov, Cora N Sternberg, Robert Motzer, Tim Eisen
BACKGROUND: Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 tyrosine kinases. This open-label, crossover clinical study (AV-951-09-902) provided access to tivozanib for patients who progressed on sorafenib in TIVO-1, comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC). METHODS: Patients enrolled in this single-arm, phase 2 crossover study were previously randomised to sorafenib on TIVO-1, progressed and then crossed over to tivozanib...
March 13, 2018: European Journal of Cancer
H Lindman, M Andersson, J Ahlgren, E Balslev, A Sverrisdottir, S B Holmberg, N O Bengtsson, E H Jacobsen, A B Jensen, J Hansen, M K Tuxen, L Malmberg, K Villman, H Anderson, B Ejlertsen, J Bergh, C Blomqvist
STUDY AIM: Retrospective studies have demonstrated a worse outcome in breast cancer patients not developing leukopenia during adjuvant chemotherapy. The SBG 2000-1 is the first randomised trial designed to compare individually dosed chemotherapy without G-CSF support based on grade of toxicity to standard-dosed chemotherapy based on body surface area (BSA). METHODS: Patients with early breast cancer were included and received the first cycle of standard FEC (fluorouracil 600 mg/m2 , epirubicin 60 mg/m2 , cyclophosphamide 600 mg/m2 )...
March 13, 2018: European Journal of Cancer
C Wilson, R Bell, S Hinsley, H Marshall, J Brown, D Cameron, D Dodwell, R Coleman
The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials reporting changes in bone mineral density as a surrogate. The AZURE trial (ISRCTN79831382) evaluated the impact of adjuvant zoledronic acid (ZOL) on fractures. The AZURE trial is an academic, multi-centre, randomised phase III study evaluating the addition of ZOL 4 mg to standard therapy (neo/adjuvant chemotherapy and/or endocrine therapy) for 5 years (administered by intravenous (iv) infusion every 3-4 weeks for 6 doses, then 3 monthly × 8 and 6 monthly × 5) in patients with stage II/III early breast cancer...
March 12, 2018: European Journal of Cancer
Haitham Mirghani, Ludovic Lacroix, Caroline Rossoni, Roger Sun, Anne Aupérin, Odile Casiraghi, Aude Villepelet, Roger Lacave, Gladwys Faucher, Virginie Marty, Charles Ferté, Jean Charles Soria, Caroline Even
BACKGROUND: Human papillomavirus (HPV)-driven oropharyngeal cancer (OPC) patients are characterised by a better prognosis than their HPV-negative counterparts. However, this significant survival advantage is not homogeneous and among HPV-positive patients those with a smoking history have a significantly increased risk of oncologic failure. The reason why tobacco consumption impacts negatively the prognosis is still elusive. Tobacco might induce additional genetic alterations leading to a more aggressive phenotype...
March 10, 2018: European Journal of Cancer
Andreas Stang, Jürgen C Becker, Paul Nghiem, Jacques Ferlay
AIM: The aim of this article was to provide worldwide, population-based incidence rates for Merkel cell carcinoma (MCC). METHODS: We included 11,576 cases from 20 countries for time trend analyses (1990-2007) and 11,028 cases (2.5 billion person-years) from 21 countries for the period 2003-2007 extracted from Cancer Incidence in Five Continents. We computed age-standardised incidence rates (World Standard population) per million person years and sex ratios of these rates...
March 10, 2018: European Journal of Cancer
Yu-Ju Chu, Hwai-I Yang, Hui-Chen Wu, Mei-Hsuan Lee, Jessica Liu, Li-Yu Wang, Sheng-Nan Lu, Chin-Lan Jen, San-Lin You, Regina M Santella, Chien-Jen Chen
BACKGROUND: Hepatocarcinogenicity of aflatoxin B1 (AFB1 ) has rarely been studied in populations with hepatitis C virus (HCV) infection and those without hepatitis B virus (HBV) and HCV infection (non-B-non-C). This case-control study nested in a community-based cohort aimed to investigate the HCC risk associated with AFB1 in HCV-infected and non-B-non-C participants. METHODS: Baseline serum AFB1 -albumin adduct levels were measured in 100 HCC cases and 1767 controls seronegative for anti-HCV and HBsAg (non-B-non-C), and another 103 HCC cases and 176 controls who were anti-HCV-seropositive and HBsAg-seronegative...
March 10, 2018: European Journal of Cancer
Tsuneo Takenaka, Yohko Kawai, Takahiro Amano
No abstract text is available yet for this article.
March 9, 2018: European Journal of Cancer
Gabriele Capurso, Livia Archibugi, Laura Tessieri, Maria Chiara Petrone, Andrea Laghi, Paolo Giorgio Arcidiacono
No abstract text is available yet for this article.
March 9, 2018: European Journal of Cancer
Gaelle Tachon, Eric Frouin, Lucie Karayan-Tapon, Marie-Luce Auriault, Julie Godet, Valerie Moulin, Qing Wang, David Tougeron
No abstract text is available yet for this article.
March 5, 2018: European Journal of Cancer
Pamela Minicozzi, Paul M Walsh, Maria-José Sánchez, Annalisa Trama, Kaire Innos, Rafael Marcos-Gragera, Nadya Dimitrova, Laura Botta, Tom B Johannesen, Silvia Rossi, Milena Sant
BACKGROUND: Cancer survival has persistently been shown to be worse for Eastern European and UK/Ireland patients than those of other European regions. This is often attributed to later stage at diagnosis. However, few stage-specific survival comparisons are available, so it is unclear whether poorer quality treatment or other factors also contribute. For the first time, European cancer registries have provided stage-at-diagnosis data to EUROCARE, enabling population-based stage-specific survival estimates across Europe...
March 5, 2018: European Journal of Cancer
R Álvarez, A Carrato, J Adeva, I Alés, S Prados, M Valladares, T Macarulla, A Muñoz, M Hidalgo
Development of hyperbilirubinaemia is common in patients with advanced pancreatic adenocarcinoma, both at diagnosis as well throughout disease evolution. For this reason, hyperbilirubinaemia determines chemotherapy treatment selection, and therefore it should be considered one of the most relevant conditions. There is very little evidence for the use of chemotherapy in this setting. This article summarises the main causes of hyperbilirubinaemia, how to treat them as well as their differential diagnosis. The current clinical evidence of the available drugs as well as the recommendations of use different combinations in the context of hyperbilirubinaemia are also reviewed...
March 2, 2018: European Journal of Cancer
Christoph Seidel, Gedske Daugaard, Alexey Tryakin, Andrea Necchi, Gabriella Cohn Cedermark, Olof Ståhl, Marcus Hentrich, Margarida Brito, Costantine Albany, Fadi Taza, Arthur Gerl, Karin Oechsle, Carsten Bokemeyer
BACKGROUND: For metastatic germ cell tumour patients with intermediate prognosis (IPGCT) according to the IGCCCG classification 5-year overall survival (OS) rates of 79% were described, but recent data suggest significant changes. PATIENTS AND METHODS: To compare the outcome of current IPGCT with former patients and to find new prognosticators a retrospective observational study was performed. Eligibility criteria were: age ≥16 years, diagnosed between 1979 and 2014...
March 2, 2018: European Journal of Cancer
Luigino Dal Maso, Chiara Panato, Silvia Franceschi, Diego Serraino, Carlotta Buzzoni, Susanna Busco, Stefano Ferretti, Antonietta Torrisi, Fabio Falcini, Manuel Zorzi, Claudia Cirilli, Walter Mazzucco, Michele Magoni, Paolo Collarile, Fabio Pannozzo, Anna Luisa Caiazzo, Antonio Giampiero Russo, Alessio Gili, Adele Caldarella, Roberto Zanetti, Maria Michiara, Lucia Mangone, Rosa Angela Filiberti, Mario Fusco, Francesca Gasparini, Giovanna Tagliabue, Rosaria Cesaraccio, Rosario Tumino, Luciana Gatti, Francesco Tisano, Silvano Piffer, Giovanna Maria Sini, Guido Mazzoleni, Stefano Rosso, Anna Clara Fanetti, Salvatore Vaccarella
AIMS: In Italy, incidence rates of thyroid cancer (TC) are among the highest worldwide with substantial intracountry heterogeneity. The aim of the study was to examine time trends of TC incidence in Italy and to estimate the proportion of TC cases potentially attributable to overdiagnosis. METHODS: Data on TC cases reported to Italian cancer registries during 1998-2012 aged <85 years were included. Age-standardised incidence rates (ASR) were computed by sex, period, and histology...
March 1, 2018: European Journal of Cancer
Ofer Margalit, Ronac Mamtani, Yu-Xiao Yang, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Einat Shacham-Shmueli, Ben Boursi
BACKGROUND: Previous studies have shown that elevated preoperative carcinoembryonic antigen (CEA) levels are associated with worse prognosis in patients with colon cancer. These studies compared the prognosis of patients with elevated versus normal CEA levels. We sought to assess the prognostic role of increasing levels of CEA in stage I and II patients who did not receive adjuvant chemotherapy. METHODS: Using the National Cancer Database (2004-2014), we identified 45,449 individuals with stage I and II colon cancer who did not receive adjuvant chemotherapy and had preoperative CEA levels available...
March 1, 2018: European Journal of Cancer
Michael Stahl, Annett Maderer, Florian Lordick, Andre L Mihaljevic, Stefan Kanzler, Thomas Hoehler, Peter Thuss-Patience, Stefan Mönig, Volker Kunzmann, Sebastian Schroll, Andreas Sandermann, Andrea Tannapfel, Hans-Joachim Meyer, Christoph Schuhmacher, Hansjochen Wilke, Markus Moehler
BACKGROUND: Perioperative chemotherapy significantly improves survival in patients with locally advanced oesophagogastric cancer (EGC). However, as approximately 60% of patients will die from their disease, new therapeutic agents such as molecular-targeted drugs are needed. PATIENTS AND METHODS: To evaluate the role of panitumumab with perioperative chemotherapy, previously untreated patients with locally advanced EGC received, in an open-label randomised phase II study (NEOPECX), standard epirubicin, cisplatin, capecitabine (ECX) chemotherapy with or without panitumumab...
March 1, 2018: European Journal of Cancer
Neill Booth, Pekka Rissanen, Teuvo L J Tammela, Kimmo Taari, Kirsi Talala, Anssi Auvinen
OBJECTIVES: Few empirical analyses of the impact of organised prostate cancer (PCa) screening on healthcare costs exist, despite cost-related information often being considered as a prerequisite to informed screening decisions. Therefore, we estimate the differences in register-based costs of publicly funded healthcare in the two arms of the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) after 20 years. METHODS: We obtained individual-level register data on prescription medications, as well as inpatient and outpatient care, to estimate healthcare costs for 80,149 men during the first 20 years of the FinRSPC...
March 1, 2018: European Journal of Cancer
Shi-Xiu Wu, Lv-Hua Wang, Hong-Lei Luo, Cong-Ying Xie, Xue-Bang Zhang, Wei Hu, An-Ping Zheng, Duo-Jie Li, Hong-Yan Zhang, Cong-Hua Xie, Xi-Long Lian, De-Xi Du, Ming Chen, Xiu-Hua Bian, Bang-Xian Tan, Hao Jiang, Hong-Bo Zhang, Jian-Hua Wang, Zhao Jing, Bing Xia, Ni Zhang, Ping Zhang, Wen-Feng Li, Fu-Jun Zhao, Zhi-Feng Tian, Hui Liu, Ke-Wei Huang, Jin Hu, Rui-Fei Xie, Lin Du, Gang Li
BACKGROUND: This randomised phase III study was conducted to investigate the efficacy of extended nodal irradiation (ENI) and/or erlotinib in inoperable oesophageal squamous cell cancer (ESCC). PATIENTS AND METHODS: Patients with histologically confirmed locally advanced ESCC or medically inoperable disease were randomly assigned (ratio 1:1:1:1) to one of four treatment groups: group A, radiotherapy adoption of ENI with two cycles of concurrent TP chemotherapy (paclitaxel 135 mg/m2  day 1 and cisplatin 20 mg/m2 days 1-3, every 4 weeks) plus erlotinib (150 mg per day during chemoradiotherapy); group B, radiotherapy adoption of ENI with two cycles of concurrent TP; group C, radiotherapy adoption of conventional field irradiation (CFI) with two cycles of concurrent TP plus erlotinib; group D, radiotherapy adoption of CFI with two cycles of concurrent TP...
February 26, 2018: European Journal of Cancer
Michela Meregaglia, John Cairns, Lisa Licitra, Paolo Bossi
BACKGROUND: There is uncertainty around the optimal surveillance of head and neck cancer patients after the primary curative treatment. This study aims at assessing the cost-effectiveness of a post-treatment programme of frequent radiological assessments (maximal approach) compared with a symptom-driven surveillance (minimal approach). MATERIALS AND METHODS: A decision-analytic Markov model is developed to assess the cost utility of two alternative follow-up programmes with a lifetime horizon...
February 22, 2018: European Journal of Cancer
Yasuhiro Hagiwara, Yasuo Ohashi, Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi, Yukiyasu Okamura, Masaru Konishi, Ippei Matsumoto, Yuji Kaneoka, Yasuhiro Shimizu, Shoji Nakamori, Hirohiko Sakamoto, Soichiro Morinaga, Osamu Kainuma, Koji Imai, Naohiro Sata, Shoichi Hishinuma, Hitoshi Ojima, Ryuzo Yamaguchi, Satoshi Hirano, Takeshi Sudo
BACKGROUND: Adjuvant chemotherapy with S-1 for resected pancreatic cancer demonstrated survival benefits compared with gemcitabine in the JASPAC 01 trial. We investigated the effect of these agents on health-related quality of life (HRQOL) of patients in the JASPAC 01 trial. METHODS: Patients with resected pancreatic cancer were randomly assigned to receive gemcitabine (1000 mg/m2 weekly for three of four weeks for up to six cycles) or S-1 (40, 50, or 60 mg twice daily for four of six weeks for up to four cycles)...
February 22, 2018: European Journal of Cancer
Thomas Melchardt, Teresa Magnes, Clemens Hufnagl, Aaron R Thorner, Matthew Ducar, Daniel Neureiter, Wolfgang Tränkenschuh, Eckhard Klieser, Alexander Gaggl, Sebastian Rösch, Gerd Rasp, Tanja N Hartmann, Lisa Pleyer, Gabriel Rinnerthaler, Lukas Weiss, Richard Greil, Alexander Egle
BACKGROUND: Tumour heterogeneity and clonal evolution within a cancer patient are deemed responsible for relapse in malignancies and present challenges to the principles of targeted therapy, for which treatment modality is often decided based on the molecular pathology of the primary tumour. Nevertheless, the clonal architecture in distant relapse of head and neck cancer is fairly unknown. PATIENTS AND METHODS: For this project, we analysed a cohort of 386 patients within the Austrian Registry of head and neck cancer...
February 22, 2018: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"